Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Neurol. 2012 Oct;69(10):1255-8.

Potential use of γ-secretase modulators in the treatment of Alzheimer disease.

Author information

  • 1Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92063, USA. slwagner@ucsd.edu

Abstract

Although significant progress has occurred in the past 20 years regarding our understanding of Alzheimer disease pathogenesis, we have yet to identify disease-modifying therapeutics capable of substantially altering the clinical course of this prevalent neurodegenerative disease. In this short review, we discuss 2 approaches that are currently being tested clinically (γ-secretase inhibition and γ-secretase modulation) and emphasize the significant differences between these 2 therapeutic approaches. We also discuss certain genetic- and biomarker-based translational and clinical trial paradigms that may assist in developing a useful therapeutic agent.

PMID:
22801784
[PubMed - indexed for MEDLINE]
PMCID:
PMC3747667
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Write to the Help Desk